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used as a confirmatory test when there are indeterminate
abnormalities on CT. There is a growing body of literature
suggesting that the standardized uptake value for FDG in
the primary tumor, a semiquantitative measure of the tu-
mor’s glucose metabolism, may help identify patients at
elevated risk for recurrence and may, therefore, identify
appropriate patients for induction therapy or adjuvant ther-
apy.6 Another body of literature addresses the hypothesis
that PET, obtained during or after induction therapy, can
predict pathologic response and identify subsets of patients
with better and worse prognoses.7-12 None of these specific
indications was tested by the current trial.
In summary, FDG-PET in patients with esophageal cancer
without evidence of metastasis after conventional workup
identified unsuspected distant metastatic disease in at least
4.8% (95% CI: 2.2%-8.9%) of cases. An additional 3.7% (95%
CI 1.5%-7.5%) had unconfirmed evidence of M1b disease and
were treated nonsurgically, at least in part owing to the PET
findings. In most cases, these PET-detected metastases should
be confirmed before excluding a patient from surgical consid-
eration, since apparent M1 findings by PET in at least 3.7%
(95% CI: 1.5%-7.5%) were false positives. An additional 5%
of patients can be expected to harbor metastatic disease that
escapes detection by both CT and PET.
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Discussion
Dr Mark J. Krasna (Baltimore, Md). First, I wish to congratulate
Dr Meyers on an excellent presentation. Following up on the
pioneering work at Washington University on PET scanning for
thoracic malignancies, the ACSOG undertook two clinical trials to
determine the role of PET scanning in our specialty. After pre-
senting their findings from Z40 on PET scanning for lung cancer,
the ACOSOG surgeons are now presenting the results of the first
multi-institutional prospective phase 2 trial for PET scanning in
esophageal cancer to put this new modality in perspective. All the
surgeons who undertook this goal are to be congratulated for their
completion of this trial. This in itself is a great accomplishment
and is an example to us all to study questions in thoracic surgery
thoroughly by clinical trial wherever possible.
The objective of this study was to see whether PET scan
avoided unnecessary surgery in 5% or more of patients with
esophageal cancer. The primary result of the study may be sum-
marized as follows: PET scan identified suggestive M1 disease,
including M1a and M1b, in 11 patients, or 4.8%. PET scan missed
M1 disease in 7 patients who underwent exploration. Also, PET
scan found that 31% of the patients had N1 disease, including
extensive N1, which sometimes led to surgeons avoiding surgery.
This is a little lower than expected for most surgical series, in
which almost two thirds of patients are found to have N1 disease.
Interestingly, this study also provides a snapshot of the current
practice among CT surgeons in managing esophageal cancer. Over
38% of the patients were referred for induction chemoradiation
therapy in this study. This adds to the recent “Patterns of Care
Survey” data from the Radiation Therapy Oncology Group that
show the inroads that surgeons have made in incorporating che-
moradiation and surgery in the treatment algorithm for esophageal
cancer, and it is supported by recent phase 2 and phase 3 studies.
Unfortunately, this also limits the interpretation of the results, as it
would have been best to compare PET to pathologic findings in
patients who were undergoing more surgery alone. I have three
questions.
First, how have you defined the role of surgery in patients with
M1a disease? On what basis do you decide not to perform resec-
tion in these patients and those with extensive N1 disease? Second,
what is the average cost of PET scanning? Do these results really
justify using this huge outlay in expenditure, in your opinion?
Finally, although there were 262 patients who were enrolled, the
ineligibility and unevaluable rate was quite high, much higher than
you expected. Given the borderline significance of these findings,
do the authors think that the results would be different, and how
would you suggest to us the take-home message be interpreted? In
other words, what is the current role of PET scan in our practice in
esophageal cancer?
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Dr Meyers. Thanks for your questions, Dr Krasna. Your first
question asked about the role of surgery in M1a, and this trial
actually left it to the surgeons to make a decision about how to deal
with their patients once they have had the PET and CT staging. If
I were to answer your question, it would represent my personal
strategy for M1a, and it includes very limited surgery. I would
offer M1a patients surgery only if they had no evidence of distant
metastatic disease and if they underwent induction therapy and
were good surgical candidates afterward. However, that question
was not addressed by this study in any way at all.
The average cost of a PET scan is around $2000. We did not
have a corollary cost-effectiveness analysis planned when this
study was initiated, but I am sure that we could use these data
to come up with an analysis to look at the benefit and cost
associations with PET scanning. I am sure that that would be a
natural follow-on to this study. PET scans cost $2000 apiece,
and when you see that it only changed the stage-directed use of
surgery in only 5% to 8% of the patients, cost is certainly a
consideration.
Finally, you asked about the question of ineligible patients and
the fallout from the number of patients enrolled to the number of
patients who were actually analyzed and how those results might
differ. Certainly the screened cohort, before and after exclusions,
is going to differ in that there will be a decrease in the apparent
yield of “new” M1 disease by the PET scan. However, I think that
the exclusions offer as close as to a real estimate of the value of
PET scan that we could report. I think in the single-center studies,
including our own, the enrollment was not as carefully scrutinized
as it was in these patients, and we found that there were quite a
number of patients with borderline CT abnormalities in whom the
PET scan was used to confirm an abnormal CT finding rather than
to look for something that was undetected by the CT scan. Those
are two different goals. The point of this study was to look at new
detection of otherwise unsuspected metastatic disease.
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